Buy Vegzelma (Bevacizumab-adcd)
Price range: €375.00 through €1,125.00
Vegzelma (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), the main driver of vasculogenesis and angiogenesis, and inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (VEGFR-2) on the surface of endothelial cells.
Vegzelma is indicated for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent or metastatic cervical cancer; and epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.
What is Vegzelma (Bevacizumab-adcd)?
On September 28, the U.S. Food and Drug Administration (FDA) approved Bevacizumab-adcd (Vegzelma), a biosimilar to Bevacizumab (Avastin), for the treatment of six cancers: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Where was Vegzelma (bevacizumab-adcd) approved?
On September 28, the U.S. Food and Drug Administration (FDA) approved Bevacizumab-adcd (Vegzelma), a biosimilar to Bevacizumab (Avastin), for the treatment of six types of cancer: metastatic colorectal cancer, recurrent or metastatic non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent or metastatic cervical cancer, and epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
The European Medicines Agency (EMA) decided that Vegzelma, in accordance with EU requirements for biosimilar medicines, has a very similar structure, purity, and biological activity to Avastin (an EMA-authorised medicine) and is distributed in the body in the same way. The data were deemed sufficient to conclude that Vegzelma performs in the same way as Avastin in terms of efficacy and safety in its authorized uses. Therefore, the Agency considered that, as with Avastin, the benefits of Vegzelma outweigh the identified risks and that the medicine could be authorised for use in the EU.
| Quantity |
100 mg/4 mL (25 mg/mL) ,400 mg/16 mL (25 mg/mL) |
|---|
Shipping and delivery
All orders will only be shipped after payment confirmation. Please enter your shipping details and select the payment method that suits you best.
Shipping costs:
You should always be clearly informed about the total price of your purchase, including delivery and any other associated costs.
You must explicitly agree to any additional charges, for example, if the retailer offers express shipping or gift wrapping.
Damaged Goods:
The retailer is responsible for all damage to the product, from shipping to receipt.
If you have purchased an item that does not match the advertised product in appearance or function, you have the right to request a repair, a replacement, or, if neither of these is possible, a refund.
- Non-delivery:
If you have not received the product within 30 days or by the agreed date, you must notify the seller and grant them a reasonable extension of the delivery period.
For example, if the seller informs you of a one-week delay due to problems with their suppliers, it seems reasonable to grant them this additional week. If, despite the extension, the seller still fails to fulfill their obligation to deliver, you have the right to withdraw from the contract and receive an immediate refund.
Related products
Buy Darzalex (Daratumumab)
Who is Darzalex (daratumumab) suitable for?
Darzalex (daratumumab) is indicated for patients with:-
Newly diagnosed multiple myeloma for which autologous stem cell transplantation is not an option (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.
-
Patients with multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone.
-
Patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (third-line therapy). For this indication, it is used in combination with pomalidomide and dexamethasone.
-
Multiple myeloma patients who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are doubly refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.
Buy Ibrance (Palbociclib)
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (hormone therapy) as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression after endocrine therapy.How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it must go through four phases. The first phase is a growth phase (G1 phase), the second a synthesis phase (S phase), the third another growth phase (G2 phase), and the final phase, in which the cell divides (M phase). Cancer cells divide extremely rapidly and pass through these four phases quickly. Palbociclib blocks the transition from the first G1 phase to the second S phase. This occurs by inhibiting cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins involved in entering the S phase [1] .
Buy Kadcyla (Trastuzumab Emtansine)
Buy Keytruda (Pembrolizumab)
Buy Opdivo (Nivolumab)
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with the following conditions:- metastatic melanoma as monotherapy or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer has progressed during or after chemotherapy
- advanced renal cell carcinoma who have previously received anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- Recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) with disease progression during or within 6 months of receiving platinum-based chemotherapy
- locally advanced, unresectable or metastatic urothelial carcinoma after progression under platinum-based therapy
- Metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan
- hepatocellular carcinoma in patients previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal cancer or cancer of the gastroesophageal junction (GEJ) with persistent pathological residual disease in patients who have received neoadjuvant radiochemotherapy (CRT).
Buy Perjeta (Pertuzumab)
What is Perjeta (pertuzumab) for?
Perjeta (pertuzumab) is indicated for the treatment of HER2-positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory or early breast cancer as part of a complete early breast cancer treatment regimen.
Reviews
There are no reviews yet.